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Background: Existence of anti-malarial generic drugs with low bioavailability marketed on sub-Saharan Africa raises
a concern on patients achieving therapeutic concentrations after intake of such products. This work compared
bioavailability of one generic tablet formulation with innovator’s product. Both were fixed dose combination tablet
formulations containing artemether and lumefantrine.
Methodology: The study was conducted in Dar Es Salaam, Tanzania, in which a survey of the most abundant
generic containing artemether-lumefantrine tablet formulation was carried out in retail pharmacies. The most
widely available generic (Artefan®, Ajanta Pharma Ltd, Maharashtra, India) was sampled for bioavailability
comparison with Coartem® (Novartis Pharma, Basel, Switzerland) - the innovator’s product. A randomized,
two-treatment cross-over study was conducted in 18 healthy Tanzanian black male volunteers. Each volunteer
received Artefan® (test) and Coartem® (as reference) formulation separated by 42 days of drug-free washout period.
Serial blood samples were collected up to 168 hours after oral administration of a single dose of each treatment.
Quantitation of lumefantrine plasma levels was done using HPLC with UV detection. Bioequivalence of the two
products was assessed in accordance with the US Food and Drug Authority (FDA) guidelines.
Results: The most widely available generic in pharmacies was Artefan® from India. All eighteen enrolled volunteers
completed the study and both test and reference tablet formulations were well tolerated. It was possible to
quantify lumefantrine alone, therefore, the pharmacokinetic parameters reported herein are for lumefantrine. The
geometric mean ratios for Cmax, AUC0-t and AUC0-∞ were 84% in all cases and within FDA recommended
bioequivalence limits of 80% – 125%, but the 90% confidence intervals were outside FDA recommended limits
(CI 49–143%, 53 - 137%, 52 - 135% respectively). There were no statistical significant differences between the two
formulations with regard to PK parameters (P > 0.05).
Conclusions: Although the ratios of AUCs and Cmax were within the acceptable FDA range, bioequivalence
between Artefan® and Coartem® tablet formulations was not demonstrated due to failure to comply with the FDA
90% confidence interval criteria. Based on the observed total drug exposure (AUCs), Artefan® is likely to produce a
similar therapeutic response as Coartem®.
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Malaria is the major cause of morbidity and mortality in the
sub-Saharan Africa (SSA) especially in children below five
years of age. Chemotherapy is the cornerstone in the man-
agement of malaria in endemic areas. Due to high resistance
rates against sulphadoxine-pyrimethamine (SP), artemisinin-
based combination therapy (ACT) containing artemether-
lumefantrine (Alu) replaced SP as first-line drug of choice
for treatment of uncomplicated falciparum malaria in many
countries of SSA, including Tanzania.
The change of malaria treatment guidelines has
been accompanied by infiltration of generic Alu tablet
formulation in the health systems of these countries.
High prices of branded products e.g. Coartem® calls
for alternative cheaper generic products. Generic for-
mulations are promoted to address accessibility and
affordability. Unfortunately, there have been disap-
pointing reports of marketing anti-malarial generic
products that are fake, substandard and with low bio-
availability in South East Asia [1], SSA and East
Africa including Kenya and Tanzania [2-8]. The use
of poor quality anti-malarial drugs threatens the life
span of ACT and may result in sub-therapeutic con-
centrations leading to poor treatment outcomes and
emergence of drug resistance. Reports on impaired
clinical response of uncomplicated falciparum malaria
due to use of poor-quality artemether and decreased
sensitivity of the parasite on artesunate were recently
published [9-11]. Already, there are sporadic reports
of resistance against ACT in some malarious regions,
creating a concern on the longevity of the currently
available and effective anti-malarial drugs in the SSA
[12-14].
This paper reports a comparative bioavailability findings
between the most available generic tablet formulation
containing artemether and lumefantrine (Artefan®) (Ajanta
Pharma Ltd-India) and Coartem® (Novartis, Basel,
Switzerland) as innovator’s product.
Methodology
Determination of the most prevalent generic
The study was conducted between February and April
2012. It was preceded by a cross-sectional survey to
reveal the most abundant and prescribed generic
formulation containing a fixed combination of Alu
tablet on the Dar es Salaam market. Among others,
Artefan® was found to be abundant and thereafter
was subjected to bioequivalence study using Coartem®
as comparator.
Sampling of tablets
Two hundred and twenty four tablets of Artefan® (test
formulation), a fixed-dose combination tablets consisting
of 20 mg of artemether and 120 mg of lumefantrine (B.No./No.LOT.P0511H, TAN 09.085.PO1BAJA, expiration
date July 2013) were purchased from one wholesale
pharmacy in Dar es Salaam. The reference formulation
Coartem® tablets (F2491, expiration date August 2013)
was donated by Dodoma Regional Hospital.
Clinical study design and ethical clearance
This was a randomized, single dose, open label, single
center, two period, two sequence crossover bioequiva-
lence (BE) study. The study protocol was reviewed
and approved by the Muhimbili University of Health
and Allied Sciences (MUHAS) and Ifakara Health In-
stitute (IHI) institutional review boards. The study
was conducted according to Good Clinical Practice.
To ensure confidentiality, identification numbers (ID
codes) were used instead of volunteers’ names.
Study area
Recruitment and enrollment of the study volunteers took
place at Bagamoyo Clinical Trial Unit in Bagamoyo district.
BCTU is part of IHI’s Bagamoyo Research and Training
Centre (BRTC). The unit is designed to conduct early phase
studies where volunteers can be retained for the entire
period of study. The facility has dedicated areas for essential
study procedures including volunteer screening, blood sam-
ple collection, investigational product preparation, ICU for
management of serious adverse events and research wards.
Determination of lumefantrine concentration in plasma
samples was performed in the MUHAS Bioanalytical labora-
tory in Dar es Salaam, Tanzania.
Study participants
Eighteen healthy adult male college students from
Bagamoyo Art Institute (TaSUBa) in Coastal region (age
18–35 years) with normal laboratory parameters and willing
to provide written informed consent were recruited and
enrolled into the study based on the pre-defined inclusion
and exclusion criteria.
Inclusion criteria
a) Healthy male > 18 years of age.
b) Availability during entire study period (two months).
c) Willingness to give written informed consent after
being informed of the nature of study.
d) Body mass index (BMI) between 18 and 30 kg/m2.
e) No history of anti-malarial drug ingestion in the past
one month.
f ) Normal Laboratory range parameters from all
performed laboratory tests at baseline (FBC, ALT,
ASAT, ALP, serum creatinine, total bilirubin and
albumin).
g) Must be literate, can speak English and understand
written English.
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a) Hypersensitivity to artemether and/or lumefantrine
or related compounds.
b) History of conditions that may alter absorption,
metabolism, or passage of drugs out of the body
(sprue, coeliac disease, Crohn's, colitis, liver, kidney,
or thyroid conditions).
c) History of mental illness, drug addiction, drug abuse.
d) A haematocrit value of ≤ 37.0%.
e) Receipt of an investigational drug within four weeks
prior to study drug dosing.
f ) Currently taking any prescription of systemically
acting medications, within seven days prior to study
dosing or over-the-counter medication within three
days of study dosing.
g) Smoking
h) Positive blood slide for malaria
i) Regular use of barbiturates, carbamazepine,
rifampicin, phenytoin, phenothiazines, cimetidine,
omeprazole, macrolides, imidazoles,
fluoroquinolones and others which can induce or
inhibit CYP450.
Participants recruitment
Recruitment was done through sensitization meetings,
which were conducted at the college premises. Permis-
sion to conduct sensitization meetings was sought from
College administration and thereafter advertisement for
the meetings was posted on the college notice board. In-
terested participants were asked to register their names and
invited to attend sensitization meeting where detailed ex-
planation and clarification about the study was given
followed by screening of potential subjects in which the po-
tentially eligible participants were identified.
Screening for eligible participants
Screening was performed to all potential subjects at
baseline and based on the inclusion and exclusion cri-
teria to get eligible participants who were then enrolled
for the entire study. Baseline screening included taking
medical history, performing physical, medical exa-
mination and blood laboratory tests. Physical and med-
ical examinations included checking vital signs and
performing Electrocardiogram (ECG). Laboratory tests
included parasitology (blood slide for malaria parasites),
haematology (FBC) and biochemistry (urea, creatinine,
total bilirubin, ALT, AST, ALP and albumin).
Enrollment
Eligible subjects were those who fulfilled the inclusion
criteria and none of the exclusion criteria. Out of 31
subjects screened, 18 were enrolled into the study and
were randomized into treatment sequence. Theparticipants were advised to abstain from eating grape
fruits and drinking grape fruit juice during the entire
period of the study [15,16].
Randomization and study procedures
The eighteen volunteers were randomly assigned to ei-
ther of the treatment sequence: test period 1, reference
period 2; or reference period 1, test period 2. At drug
administration, the pharmacist opened a sealed en-
velope with the corresponding treatment number, which
contained the drug allocation for the treatment period,
and appropriate drug was administered. The investiga-
tors were blinded on the drug, which each volunteer
took. The randomization code was kept in the BCTU
Data Unit and was decoded (broken) after all the PK
analysis had been completed.
Drug administration, blood sampling and subject
follow-up
Each enrolled volunteer received a single adult dose (80/
480 mg artemether and lumefantrine respectively) of ei-
ther Coartem® or Artefan® with a glass of water (200 ml)
under supervision of the pharmacist followed by stan-
dardized fatty meal. After a 42-day washout period, the
volunteers took the alternative drug. On the day of en-
rolment participants were admitted and retained at the
BCTU for three days (72 hours).
Subjects were discharged and returned to BCTU at
168 hours for one blood sample collection and allowed
back to college. On each period all subjects underwent
clinical evaluations to monitor for adverse drug reactions
and assess medication tolerability . This was done at 0.5,
2, 4, 6, 8, 10, 12, 24, 48, 72 and 168 hours post dosing.
Blood sampling and sample processing
A total of 18 eligible volunteers were enrolled to partici-
pate in this study. FDA allows a minimum number of 12
volunteers for bioequivalence study [17,18]. The enrolled
volunteers arrived at the BCTU for stay after an over-
night fasting. Written informed consent was obtained
from each volunteer before participation.
Subjects had a heparinized saline lock placed in an
arm to obtain serial venous blood samples for plasma
drug concentrations for the first 24 hours. Each subject
had a predose blood sample drawn (time = 0) and took
an observed dose of the test or reference drug. Subse-
quent blood samples were drawn at 2, 4, 6, 8, 10, 12, 24,
48, 72 and 168 hours after the dose [19]. After a 42-day
washout period, the subjects took an observed dose of
the alternative Alu formulation. Study procedures and
blood sampling were repeated as described previously.
Each subject had 22 blood samples (3 ml each) drawn
over the course of the study for determination of
lumefantrine plasma concentrations. The total amount
Table 1 Volunteers demographic and baseline
characteristics (n = 18)
Parameter Value
Age (years ± SD) 27 ± 7.3
Weight (Kg ± SD) 67.3 ± 12.6
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from each volunteer was 66 ml.
The blood samples were collected in heparinized
vacutainers. Each vacutainer was appropriately labeled
with Brady number, subject’s identification number (ID),
sampling time, sampling hour and date. Blood samples
were kept in a cool box and transported within
45 minutes to a BRTC laboratory for centrifugation. The
samples were centrifuged at 1800 g at 4°C to obtain
plasma samples which were transferred into similarly
labeled cryovials. The plasma samples were kept in IHI’s
BRTC laboratory at −80°C until transfer to MUHAS-
Bioanalytical Laboratory in Dar es Salaam. The samples
were carried in a cool box packed with liquid nitrogen.
At MUHAS plasma sample were kept at -80°C until the
day of analysis.
Bioanalytics
Blood samples were analysed at MUHAS Bioanalytical
laboratory. The plasma analysis for lumefantrine deter-
mination was done using an HPLC method with UV de-
tection. The method was developed by ACC laboratory
in German in collaboration with MUHAS Bio-analytical
Laboratory. The details of the method have been pub-
lished elsewhere [20].
Chromatographic conditions
The mobile phase was prepared by dissolving 4.76 g of
di-potassium hydrogen phosphate tri-hydrate in 350 ml
distilled water. The obtained solution was mixed with
650 ml acetonitrile and the mixture was adjusted to a
pH of 3.1 with ortho-phosphoric acid. The pre column
(LiChrospher 100) RP 18, 5 μm; 5 × 4 mm and the col-
umn (LiChrospher 100) RP18, 5 μm; 125 × 4 mm was
used. The flow rate was 1.2 ml/min, detection was
achieved at 335 nm and the total run time was 20 min.
Method validation
The method was validated in which inter-day method;
linearity, precision and accuracy were assessed by pro-
cessing one validation batch each day for three different
days. Precision and accuracy of the method was deter-
mined using quality control samples spiked at three dif-
ferent concentrations. Low, medium and high quality
control samples (QCL, QCM and QCH) were used in
three runs performed on different days.
Pharmacokinetic and statistical analysis of lumefantrine
The pharmacokinetic parameters (Cmax, Tmax, AUC0-168,
and AUC0-∞) of reference and test drugs were compared
using ANOVA with period and sequence as within
and between subject factors respectively. Analysis was
performed in line with FDA bioequivalence guidelines.
Bioavailability/bioequivalence was determined using areaunder the plasma concentration–time curve predose to
the last measurable plasma concentration (AUC0-168),
AUC extrapolated to infinity (AUC0-∞), peak plasma
concentrations (Cmax) and time required to attain peak
concentration (Tmax).
Non-compartmental PK analysis was employed to de-
termine PK profile of lumefantrine of each tablet formu-
lation using R Statistical software version 2:13. The Cmax
and Tmax were determined directly from plasma concen-
trations –time curve. AUC0-168 was calculated by a com-
bination of linear and logarithmic trapezoidal methods.
AUC0-∞ was calculated by the summation of AUC0-168
and residual AUC (AUC0-168 + C168/λz), where λz is ter-
minal elimination rate constant. The λz was estimated
by performing log-linear regression on the concentration
versus time data points that were determined to describe
the terminal, linear elimination phase.
Individual pharmacokinetic parameters were natural
log-transformed according to FDA recommendations
[17,18], and geometric means and standard deviations
calculated. The ratio of the test to reference formulation
for geometric mean Cmax, AUC0-t, and AUC0-∞ and the
90% confidence intervals around each mean ratio were
determined. Samples below limit of quantitation (LLOQ)
were assigned a 50 ng/ml value during estimation of PK
parameters. Average bioequivalence would be met if the
90% confidence intervals around the Cmax, AUC0-168,
and AUC0-∞ mean ratios for each drug lied within the
FDA's predefined limits of 0.80 to 1.25 [17,18].
Results
Volunteers and baseline characteristics
Table 1, describes the demographic characteristics, mean
baseline haematology, and biochemistry of the 18 study
volunteers who completed the study. Both test and refer-
ence drug formulations were well tolerated. There were
no adverse drug reactions, abnormal laboratory results
or dropouts.
Lumefantrine method validation
The inter-day accuracy and precision of the method
were within the acceptable limits. The coefficients of





% Ratio of test to
reference
Norvatis Data on file
(Riamet)
Arithmetic mean ± SD Arithmetic mean ± SD Arithmetic mean
(*) (*)
Tmax (h) 6.11±2.698 6.2±2.2 0.8950 - 6 – 8














0.7022 84.3 108000- 243000
*Geometric mean.
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three runs performed on different days fulfilled the ac-
ceptance criteria as were always ≤15%. The relative
standard deviations from the nominal value for QCL,
QCM and CQH in all runs were always ≤15%. A total of
394 test plasma samples were analysed in eight batches
and the peaks were well separated
Bioavailability and mean bioequivalence data
The results of PK parameters are presented as mean ±
SD with reference to lumefantrine (Table 2). The pri-
mary PK parameters Cmax, Tmax, AUC0-168 and AUC0-∞
for Artefan® and Coartem® formulations were deter-
mined under fed condition. The Cmax of lumefantrine
for both drugs was achieved within 6.22 hours (Table 2).
The mean residual AUCs extrapolated to infinity was
similar for both formulations with 10.44% for Artefan®
and 9.78% for Coartem (P-value = 0.95).
Plasma concentrations of lumefantrine attained by ad-
ministration of a single dose of Artefan® and Coartem®
formulations were comparable based on lumefantrineFigure 1 Mean plasma concentration-time profiles of lumefantrine in
20/120 mg Coartem® or Artefan® (generic) tablet formulation. Error- Bconcentration-time profiles for Artefan® and Coartem®
formulations (Figure 1).
Mean ratios of Artefan® to Coartem® natural log-
transformed Cmax, AUC0-168, and AUC0-∞ values and
90% confidence interval limits are summarized in
Table 3. One out of the 18 subjects had predose
lumefantrine concentration above the lower limit of
quantitation (50 ng/mL) in period 1 even after the wash-
out period. Other six volunteers had lumefantrine
predose concentrations ranging from 50.6 to 221.6 ng/
mL. Of the six subjects, four had lumefantrine in period
one (55–190 ng/mL) and the rest had lumefantrine (50.6
to 221.6 ng/mL) after the wash out period, and all were
included in the lumefantrine pharmacokinetic analysis as
concentrations at time zero. However, none of the sub-
jects had a predose concentration greater than 5% of his
lumefantrine Cmax and thus all concentrations were ac-
ceptable for inclusion in average bioequivalence analysis
in accordance with FDA recommendations.
Artefan® lumefantrine Cmax, AUC0-t and AUC0-∞ geo-
metric means were all less by ~ 16% relative to Coartem®.18 health volunteers after oral administration of either a
ars represent mean ± standard error.
Table 3 Confidence interval from log transformed data for Bioequivalence assessment
Pharmacokinetic parameters Ratio of Artefan® to
Coartem® (%)
90% Confidence interval
of the geometric mean ratio
Acceptance criteria P-value (normal)
LnCmax 84.0 49 - 143% 80 - 125% 0.559
LnAUC0-168 84.5 53 - 137% 80 - 125% 0.538
LnAUC0-∞ 84.3 52 - 135% 80 - 125% 0.575
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and AUC0-∞ for fulfilling the FDA criteria for bioequiva-
lence are 0.8 – 1.25 and were met. However, as illus-
trated by Figure 2, the 90% confidence intervals for
lumefantrine Cmax, AUC0-t, and AUC0-∞ mean ratios
were not within 80 -125% and, therefore, FDA criteria
for average bioequivalence was not met.
The mean day 7 lumefantrine plasma concentrations
obtained from Artefan® and Coartem® were 163 and
171 ng/ml whereas the median values were 102 and 147
respectively 171 ng/ml indicating that the test and refer-
ence tablet formulations were comparable.Discussion
The obtained mean residual AUC values (≤10%) for both
Artefan® and Coartem® with estimated AUC0-168 of 80%
indicate that the selected sampling scheme was sufficiently
long enough to ensure adequate description of the elim-
ination phase of lumefantrine.
The obtained mean PK parameters for Artefan® and
Coartem were found to have no statistically significant
difference (p> > 0.05). The mean AUC values of
lumefantrine for both Artefan® and Coartem® were
within range of 108,000 and 243,000 ng.h/ml obtained
by Novartis (see Table 2). This means that both Artefan®
and Coartem® had comparable bioavailability and wouldFigure 2 The 90% confidence interval for average
bioequivalence measures (Cmax and AUC) plotted over the
FDA bioequivalence criteria boundary (The red dotted lines
represent the FDA recommended lower and upper limits of the
90% confidence interval for Test/Reference ratio).equally achieve comparable therapeutic plasma lume-
fantrine concentrations.
Lumefantrine day 7 plasma concentration is predictive
of the treatment outcome in malaria patients who
complete the six doses taken for three consecutive days.
Patients with lumefantrine levels below 175 ng/ml on
day 7 are more likely to experience recrudescence by
day 21 or 28 allowing prediction of treatment failure
[21]. In this study, the patients took a single Alu dose
(4 tablets) and the mean day 7 lumefantrine levels were
163.00 ±148.01 and 171.82 ±116.59 for Artefan® and
Coartem® respectively (p-value = 0.98). Despite taking a
single dose versus six doses recommended for non-
severe malaria treatment, the mean day 7 plasma con-
centration values were very close to the cut off point
and had no statistical significant difference from the lat-
ter (175 ng/ml) indicating that both Artefan® and
Coartem® are likely to produce adequate drug plasma
concentrations to exert antiplasmodial action. The mean
and median day 7 lumefantrine plasma concentrations
obtained from Artefan® and Coartem®, respectively, were
comparable. However, due to observed high inter-
individual variability in lumefantrine plasma concentra-
tions, there is possibility of occurrence of treatment
failure or drug toxicity in some individuals treated with
either Coartem® or Artefan®.
In assessing bioequivalence between Artefan® and
Coartem® it was observed that the geometric mean ratios
for Cmax, AUC0-t and AUC0-∞ were within the acceptable
FDA criteria for bioequivalence of 0.8 – 1.25 (Table 3).
The overall lumefantrine pharmacokinetic profiles (phar-
macokinetic parameters) for both Artefan® and Coartem®
in the healthy Tanzanian volunteers by visual inspection
appear to be comparable (see Figure 1).
However, the 90% confidence intervals for lumefantrine
(18 subjects) Cmax, AUC0-168, and AUC0-∞ mean ratios
were not within 0.80 to 1.25 (Table 3). Figure 2 is a Forest
plot indicating 90% confidence interval limits for the ra-
tios of Cmax, AUC 0–168 and AUC 0-∞ obtained by the
study and indicates the required limits in line with FDA
requirements for BE studies. As shown in the plot, the
two tablet formulations could not meet the FDA criterion
for bioequivalence. Failure to comply with the FDA 90%
confidence intervals may be due to high variability
of lumefantrine plasma concentrations observed among
individual subjects.
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concentration observed in this study could also be due to
difference in the capacity of individuals to handle the drug
with respect to cytochrome 3A4 (CYP3A4) as well as incon-
sistency in the extent of drug presentation in the systemic
circulation through the gastro-intestinal tract. CYP3A4/5 is
expressed in the human small intestine and liver and con-
tributes to the first pass effect of lumefantrine [22].
Lumefantrine is a substrate of CYP3A4/5 which has been
shown to be polymorphic. Therefore, drugs undergoing first
pass effect by this isoform are expected to have highly vari-
able pharmacokinetics.
Conclusion
Although the ratios of AUCs and Cmax were within the
acceptable FDA range, bioequivalence between Artefan®
and Coartem® tablet formulations could not be demon-
strated due to failure to comply with the FDA 90%
confidence interval criteria. It is the failure to comply
with 90% confidence interval stipulated by FDA guide-
lines, which made the two tablet formulations to be
bioinequivalent. However, based on the observed total
drug exposure (AUCs and day 7 plasma lumefantrine
concentrations), Artefan® is likely to produce a similar
therapeutic response as Coartem®.
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